Secondary analysis (substudy, 27 patients) of a phase 2 RCT of upadacitinib in nonsegmental vitiligo: 3D imaging correlated highly with F-VASI at baseline (r=0.85) and for week-24 change (r=0.71), but not at week 52 (r=0.01).
Secondary analysisn = 27 patients
Ganesan et al. Three-dimensional imaging for facial vitiligo: Results from a phase 2 randomized controlled trial investigating upadacitinib in patients with vitiligo